Interleukin 1 receptor type II (IL1R2), also known as CD121b, is a transmembrane protein and member of the IL-1 receptor family. It is found on B lymphocytes, neutrophils, monocytes, large granular leukocytes and endothelial cells. Like IL1R1, IL1R2 can bind all three forms of IL-1 (IL-1α, IL-1β and IL-1RA) but does not transmit IL-1 signals (1). In addition to the membrane-bound form, IL1R2 also exists as the soluble form and either acts as a decoy receptor that inhibits IL-1 action by blocking the binding of IL-1 to the type I receptor complex (2). Furthermore, IL-4 is reported to antagonize the activity of IL-1 by inducing the expression and release of IL1R2. Recombinant soluble IL1R2 is thus a potent antagonist of IL-1 action and serves as a potential therapeutic target (3). IL1R2 is involved in the control of the pro-inflammatory state that takes place in the endometrium during the premenstrual and menstrual periods. IL1R2 can neutralize IL-1β and counteract its effect on endometrial stromal cells, and therefore may provide a new clinical strategy for the treatment of endometriosis (4).

ftlqpaa htgaarscrf rgrhykrefr legepvalrc pqvpywlwas vsprinltwh kndsartvpg eeetrmwaqd galwllpalq edsgtyvctt rnasycdkms ielrvfentd aflpfisypq iltlstsgvl vcpdlseftr dktdvkiqwy kdsllldkdn ekflsvrgtt hllvhdvale dagyyrcvlt fahegqqyni trsielrikk kkeetipvii splktisasl gsrltipckv flgtgtpltt mlwwtandth iesaypggrv tegprqeyse nnenyievpl ifdpvtredl hmdfkcvvhn tlsfqtlrtt vke